Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares. Veterinary pharmaceutical manufacturers have endured their ...

Vesnaandjic/E+ via Getty Images Zoetis (NYSE:ZTS) is a leading animal pharmaceutical company, primarily focused on both companion pets and livestock. Zoetis boasts a robust portfolio of long-lasting blockbusters, benefiting from lower R&D costs and quicker development timelines compared to human pharmaceuticals. However, valuation concerns persist amidst reliance on key drug launches for future growth. One-Minute Summary of Zoetis' Business Here are some key highlights of Zoetis' business and industry i ...

Core Insights - Zoetis Inc. is a leading company in the animal healthcare sector, demonstrating strong fundamentals and a significant global presence, with a 10-year total return of nearly 500% [2] - The company has raised its guidance for FY2024, reflecting confidence in its growth drivers, particularly in the Companion Animal segment, which has shown 20% YoY operational growth in Q1 [4] - Despite recent negative media coverage regarding its products, Zoetis maintains that the reported side effects are minimal, with only 1% of 18 million doses administered experiencing issues [4] Company Overview - Zoetis operates with an integrated approach to animal care, focusing on a diverse portfolio that includes both Companion Animal and Livestock segments [3] - The Companion Animal segment is the primary revenue driver, while Livestock remains important but faces challenges due to macroeconomic factors in regions like China and Argentina [3] Financial Performance - Zoetis is projected to achieve an adjusted EBITDA margin of 43.4% in FY2024, slightly below the previous year's 43.6% [6] - The company has a strong profitability grade of "A+" and continues to outperform its peers in the healthcare sector [2][6] Market Sentiment - The stock has shown resilience, recovering from a selloff in April and demonstrating a bullish long-term trend, although it faces resistance around the $200 level [7] - Despite a significant growth premium and some downgrades in estimates, the market appears to be satisfied with Zoetis's reassurances regarding its products [6][7] Product Outlook - Zoetis is optimistic about its products Librela and Solensia, projecting combined peak sales of $1 billion globally, with expectations for significant market share gains outside the US [4] - The CEO emphasized that the majority of users have reported satisfaction with the monoclonal antibodies, suggesting that negative feedback may have been overstated [4]

JHVEPhoto Just over a year ago, I thought Zoetis Inc. (NYSE:ZTS), the undisputed leader in the animal health industry, was fairly valued even at premium valuation multiples given that the company enjoys durable competitive advantages stemming from its scale and brand recognition. Since then, Zoetis stock has gained just 2% while the S&P 500 has soared almost 30%. This underperformance, if continued for longer, may spook investors, but I believe long-term investors should double down on ZTS stock because ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On April 12, 2024, The Wall Street Jou ...

Zoetis (ZTS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this animal health company have returned +0.7% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Drugs industry, to which Zoetis belongs, has gained 0.1% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...

Core Insights - Zoetis, Inc. reported first-quarter 2023 adjusted earnings of $1.38 per share, exceeding the Zacks Consensus Estimate of $1.34 and up from $1.31 in the same quarter last year [1] - Total revenues for the quarter increased by 10% year over year to $2.19 billion, surpassing the Zacks Consensus Estimate of $2.14 billion [1] Quarterly Highlights - The U.S. segment revenues rose 16% year over year to $1.16 billion, beating the Zacks Consensus Estimate of $1.1 billion [3] - Companion animal product sales in the U.S. surged 25%, driven by monoclonal antibody products for osteoarthritis pain and other key dermatology products [3] - International segment revenues grew 3% year over year to $1.007 billion but fell short of the Zacks Consensus Estimate of $1.026 billion [4] Product Performance - Livestock product sales declined by 7% in the reported quarter, primarily due to lower cattle product sales [4] - Companion animal product sales in the international segment increased by 10% on a reported basis, driven by growth in key products [4] - Livestock product sales decreased 4% year over year on a reported basis but grew 2% operationally, with price increases contributing to growth in cattle and poultry portfolios [5] 2024 Guidance - Zoetis has lowered its 2024 adjusted earnings guidance to a range of $5.71-$5.81 per share from the previous $5.74-$5.84 [7] - Projected revenues for 2024 are between $9.05 billion and $9.2 billion, indicating operational growth of 8.5-10.5% [7] Strategic Developments - In April 2024, Zoetis announced a definitive agreement to divest its medicated feed additive product portfolio for $350 million to Phibro Animal Health, aligning with its capital allocation strategy [9] - The divestment aims to focus investments on animal health solutions, productivity, and sustainability [9]

Zoetis Inc (NYSE:ZTS) Q1 2024 Results Conference Call May 2, 2024 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley David Westenberg - Piper Sandler Brandon Vazquez - William Blair Christopher LoBianco - TD Cowen Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Glen Santangelo - Jeffe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-069 ...

Zoetis (ZTS) reported $2.19 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $1.38 for the same period compares to $1.31 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.14 billion, representing a surprise of +2.36%. The company delivered an EPS surprise of +2.99%, with the consensus EPS estimate being $1.34.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...